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Abstract. To determine whether the slope of a maximal bronchial challenge test (in
which FEV1 falls by over 50%) could be extrapolated from a standard bronchial
challenge test (in which FEV1 falls up to 20%), 14 asthmatic children performed a
single maximal bronchial challenge test with methacholine (dose range: 0.097–
30.08 mmol) by the dosimeter method. Maximal dose-response curves were in-
cluded according to the following criteria: (1) at least one more dose beyond a
DFEV1 ù 20%; and (2) a MFEV1 ù 50%. PD20 FEV1 was calculated, and the
slopes of the early part of the dose-response curve (standard dose-response slopes)
and of the entire curve (maximal dose-response slopes) were calculated by two
methods: the two-point slope (DRR) and the least squares method (LSS) in %
DFEV1 × mmol−1. Maximal dose-response slopes were compared with the corre-
sponding standard dose-response slopes by a paired Student’s t test after logarithmic
transformation of the data; the goodness of fit of the LSS was also determined.
Maximal dose-response slopes were significantly different (p < 0.0001) from those
calculated on the early part of the curve: DRR20% (91.2 ± 2.7 DFEV1% z mmol−1)
was 2.88 times higher than DRR50% (31.6 ± 3.4 DFEV1% z mmol−1), and the LSS20%
(89.1 ± 2.8% DFEV1 z mmol−1) was 3.10 times higher than LSS50% (28.8 ± 1.5%
DFEV1 z mmol−1). The goodness of fit of LSS50% was significant in all cases,
whereas LSS20% failed to be significant in one. These results suggest that maximal
dose-response slopes cannot be predicted from the data of standard bronchial chal-
lenge tests.
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Introduction
Bronchial hypersensitivity to inhaled pharmacologic agents such as methacholine and
histamine is one of the hallmarks of asthma. This means that in asthmatic patients the
provocative dose (PD) or concentration (PC) that induces a 20% fall in the FEV1 is
lower than in normal subjects. Although PD and PC are the indexes used most com-
monly in bronchial challenge tests, giving information about the degree of bronchial
sensitivity to the inhaled agent [6, 11, 32], it is not possible to describe the severity of
airway narrowing, based on these parameters alone. This means that asthmatics with
similar PDs may reach different degrees of airway obstruction if further doses are
inhaled. Thus, the degree of airway sensitivity to a pharmacologic agent provides only
a partial information about the severity of bronchial hyperresponsiveness. Furthermore,
the effects of antiasthma drugs such as inhaled corticosteroids are frequently monitored
by bronchial challenge tests with methacholine and histamine, and PD and PC are the
parameters chosen to express the results; however, these changes are often very small
[5, 33].
In 1993, the European Respiratory Society (ERS) [29] published recommendations
for bronchial challenge tests, indicating that complete information from a bronchial
challenge test with pharmacologic agents can only be obtained from analysis of the
shape of the dose-response curve (DRC). It is clearly stated in this report that, although
PD or PC indicates the position of the DRC, the slope and the degree of maximal
obstruction provide relevant information about the level and potential severity of
bronchial response [9, 27, 29]. Woolcock et al. [34] were the first to demonstrate that
the shape of DRC in asthmatics was different from that of normals, i.e. many asth-
matics show a higher slope and a higher maximal response or plateau when exposed to
high doses of methacholine, histamine, or other inhaled bronchoconstrictors [2, 15, 21,
22, 24]. However, although the ERS report [29] considered that maximal DRCs,
mandatory for the study of maximal response, can be safely recorded up to a 50%
decline in FEV1, provided the patients have normal baseline lung function, it is also
recommended that this procedure should be limited to research studies. Thus, in a
clinical setting, most of the information that can be obtained from bronchial challenge
tests with pharmacologic agents comes from the analysis of the early part of the DRC.
Moderate and severe asthmatics are characterized by excessive bronchial narrow-
ing. Such patients do not usually exhibit the stable response (plateau) common in
normal subjects or patients with mild asthma. Consequently, in the absence of a
plateau, the dose-response slope (DRS) is the only index that may be used to describe
the shape of DRC and hence the severity of bronchial response. Although its main
application is for epidemiologic studies, the DRS has also been used in clinical [3, 25]
and pathophysiologic research [7, 31], which often includes the study of patients with
moderate to severe asthma. However, there is still some controversy concerning the
methods used to calculate and analyze the DRS. First, different groups use different
methods to estimate the slopes, and there is no one single model that provides the best
fit to all DRCs of asthmatics. Second, although it is known that a linear relationship can
be inaccurate in describing the shape of DRCs, the more frequently used methods are
the simple linear regression [1, 10, 24, 34] using the least-squares method and the
dose-response ratio, or two-point slope, first described by O’Connor et al. [17]. Third,
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the slope is more often determined on standard DRCs (SDRCs) [2, 3, 15, 17, 21, 22,
34] than in maximal DRCs (MDRCs) even in clinical settings [7, 14, 31, 34], and it is
not yet clear which portion of the DRC is most important. Although different math-
ematical models [2, 9, 10, 17, 28, 31] have been used to describe and/or predict the
shape of individual DRCs, we are not aware of any studies determining whether the
linear slope of the DRC in asthmatic patients changes significantly when high doses of
methacholine are inhaled.
The aim of this study was to determine whether the slope of a maximal bronchial
challenge test (in which FEV1 falls by more than 50%) could be extrapolated from a
standard bronchial challenge test (in which FEV1 falls up to 20%). This may be
relevant when deciding whether standard or maximal bronchial challenge tests should
be chosen if the slope is used to monitor the degree of bronchial hyperresponsiveness
in clinical research protocols.
Materials and Methods
Study Subjects
The data on the subjects included in the present study are summarized in Table 1. Fourteen asthmatic children
(five females and nine males), aged 9–17 years, whose parents gave their consent after an oral explanation
about the protocol, were included. According to their clinical symptoms and/or the daily medication required,
ten patients were classified as having moderate to severe asthma, and four were labeled as mild persistent
[16]. At the time of the test, all children were clinically stable and free from upper respiratory infections for
at least 6 weeks. Baseline FEV1, determined as described below, was >70% of the predicted value (Table 1).
Table 1. Subject characteristics and PD20 FEV1 and MFEV1
Subject
no.
Sex Age
(years)
Height
(cm)
Baseline FEV1
(% predicted)
PD20 FEV1
(mmol)
MFEV1a
(% postsaline)
1 M 10 145 81 0.29 −54
2 M 13 153 124 0.16 −54
3 F 17 161 108 0.39 −50
4 M 9 134 97 3.76 −46
5 F 13 150 72 0.03 −50
6 M 14 155 108 0.09 −58
7 F 15 169 82 0.86 −50
8 F 14 163 114 0.40 −50
9 F 13 147 74 0.11 −62
10 M 17 178 76 0.17 −50
11 M 12 151 105 0.16 −52
12 M 9 132 102 0.25 −57
13 M 12 139 108 3.38 −30b
14 M 9 143 103 0.36 −50
Mean ± S.D. 5F/9M 12.6 ± 2.7 151.4 ± 13.1 96.7 ± 16.5 0.74 ± 1.22 50.9 ± 7.3
a MFEV1, maximal reduction of FEV1 postchallenge
b DRC with plateau average of two points
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Inhaled bronchodilators and oral theophylline compounds, when used, were withheld at least 8 and 12 hr,
respectively, before the test [29]. Five patients were taking daily inhaled corticosteroids, two cromolyn
sodium and two ketotifen, and this treatment was maintained.
Study Design
All children performed a single bronchial challenge test with methacholine. Double doses of methacholine
were administered with a dosimeter up to a 50% reduction compared with the postsaline FEV1 or until a
plateau response was reached. To determine if the degree of airway obstruction to high doses of methacholine
could be predicted from a standard bronchial challenge test, the slopes of MDRC were compared with those
obtained on the early part of the same dose-response curve (SDRC).
The slopes were calculated by two methods: the two-point slope or dose-response ratio (DRR) as
described by O’Connor et al. [17], and the least squares method (LSS).
The study design was approved by the Scientific Council of the Faculty of Medical Sciences, as part
of a master’s thesis.
Methacholine Challenge Test
Forced expiratory maneuvers were measured using a pneumatocograph (model Compact, Vitalograph, Buck-
ingham, England). Baseline and postchallenge FEV1 were recorded as the maximum of three consecutive
measurements that agreed with each other within 5%.
The methacholine challenge test was performed using a modified dosimeter method [8], following the
European Respiratory Society recommendations [29]. Aerosols were delivered from a dosimeter (model
MB3 Mefar, Brescia, Italy) at 20 p.s.i., with an airflow of 8 liters/min and with a nebulizer output of 30.8
ml/five puffs of 0.6 s each. After inhalation of saline, and if the FEV1 postsaline fell no more than 10% from
baseline value, double cumulative doses of methacholine chloride ranging from 0.097 to 30.08 mmol were
administered. The aerosols were inhaled by fast inspiratory maneuvers from functional residual capacity
(FRC) to total lung capacity (TLC), without breath holding. All subjects wore a nose clip during aerosol
inhalation and spirometry. Measurements of FEV1 postchallenge were performed 90 s after saline and after
each dose of methacholine. The test was interrupted if one of the following occurred: (1) a FEV1 decline
ù50%; (2) a plateau was reached, i.e., when the last two response values showed a variation of less than 5%
between each other; (3) at the subject’s request due to respiratory symptoms; or (4) after the last dose (30.08
mmol) had been given.
Airway sensitivity was expressed as the PD20 FEV1, obtained from the semilogarithmic DRC by linear
interpolation of the last two points, according to the formula recommended by ERS [29].
Maximal bronchoconstrictor response (MFEV1) was expressed as the maximal percentage fall in FEV1
[29, 34]; otherwise, whenever the response reached a plateau the data points on the plateau were averaged
[30–32].
Data Analysis
The curves were included in the statistical analysis according to the following criteria: (1) at least one more
dose beyond a FEV1 reduction ù20%, and (2) a MFEV1 ù50% without plateau.
Least Squares Slope
As shown in Figure 1, methacholine DRSs were determined by the LSS in two ways: (1) with all data points
of MDRCs (LSS50%) from the first to the last cumulative dose or to the first cumulative dose at which a
plateau response ù50% was reached [7]; and (2) from the first dose of methacholine to the cumulative dose
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at which FEV1 reduction was ù20% from postsaline value (LSS20%) [10]. Only the LSS with at least three
data points were included in the analysis.
Two-point Slope (DRR)
The slope of the straight line between the origin and the final cumulative dose was also determined by the
simplified formula (Equation 1), the two-point slope or DRR proposed by O’Connor et al. [17]:
DRR 4 DFEV1 (*)/dose % DFEV1 × mmol−1 [Eq. 1]
(*) DFEV1 (%) 4 [(postsaline FEV1 − last FEV1)/postsaline FEV1] × 100
Statistical Methods
The goodness of fit of LSS was expressed by the coefficient of determination r2, and the linear regression
was considered significant if p < 0.05. The median of the number of points included in the calculation of
LSS20% and LSS50% was also determined.
A Kolmogorov-Smirnov one-sample test was used to compare the distributions of the LSS and DRR
with the normal distribution, and the Levene test was applied to test the homogeneity of variances. After
logarithmic transformation (log 10), the distributions of the maximal and standard DRS in this group were
not significantly different from the normal, and the variances between groups (DRR20% and DRR50%;
LSS20% and LSS50%) were homogeneous.
Paired Student’s t tests were performed to compare the slopes of the SDRC with those determined using
all data points in the MDRC: (1) LSS20% with LSS50% and (2) the standard dose-response ratio (DRR20%)
with maximal dose-response ratio (DRR50%). The differences were considered statistically significant if p <
0.05.
After statistical analysis, the results were recalculated into the standard form and the results expressed
as geometric mean ± S.D.
Results
From Table 1 it is apparent that all children tested had hypersensitivity to methacholine
(range PD20, 0.03–3.76 mmol), and 12 reached a FEV1 decline ù50%. Two subjects
Fig. 1. Data points used to calculate the slopes from standard and maximal DRCs.
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were excluded. In subject 4 the test was stopped because of breathlessness, and subject
13 reached a plateau at 30%. Therefore, it was possible to compare the slopes in 12
subjects, whose individual DRC are shown in Figure 2.
In Table 2 it is shown that the coefficients of determination of LSS20% and LSS50%
were all above 0.80. LSS50% reached statistical significance (p < 0.05) in all cases,
whereas LSS20% failed to be significant in just one case, with only three points included
in the regression. Since there were no zero or negative slopes, there was no need to add
a constant prior to the logarithmic transformation.
Comparison of MDRS with SDRS
The individual values of MDRS and SDRS calculated by both methods are represented
in Figure 3. MDRSs were significantly different (p < 0.0001) from those determined in
the early part of the same DRC. The slopes calculated on the early part of the DRC
were higher than MDRS, both with the DRR [DRR20% (91.2 ± 2.7 % DFEV1 × mmol−1)
was 2.88 times higher than DRR50% (31.6 ± 3.4 DFEV1 % × mmol−1)] and with the LSS
[LSS20% (89.1 ± 2.8 % DFEV1 × mmol−1) was 3.1 times higher than LSS50% (28.8 ±
1.5 % DFEV1 × mmol−1)].
Fig. 2. Individual DRCs from the 12 subjects.
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Discussion
The purpose of the present study was to determine if MDRS could be extrapolated from
the slope of a standard bronchial challenge test, which is still the recommended pro-
cedure to evaluate the degree of bronchial hyperresponsiveness in clinical and epide-
miologic protocols. From the analysis of this group of asthmatic children it was clear
that the degree of airway narrowing induced by a maximal bronchial challenge test with
methacholine could not be predicted from the slopes determined in the early part of the
same MDRC. The following differences between SDRS and MDRS were observed
with both methods of calculation of the slopes. First, both mean DRR20% and LSS20%
(standard slopes) overestimated almost by three times the slopes measured on the same
DRC using all data points up to a fall of 50% or more from baseline (maximal slopes).
Second, although these methods of assessing the DRC are oversimplified because both
assume that the dose-response relationship is linear, the analysis of the goodness of fit
Table 2. Goodness of the fit of LSS20% and LSS50% (n 4 12)
No. pointsa
(min − max)
No. points
(median)
r 2b No. slopes with
r 2 ù 0.95
No. slopes with
p > 0.05c
LSS20% 3–8 4.5 0.83–0.99 10 11
LSS50% 4–9 6 0.88–0.99 11 12
a No. points, number of points included; min, minimum; max, maximum
b r2, coefficients of determination of linear regression
c p, statistical significance of linear regression
Fig. 3. Comparison between individual slopes calculated by the two methods (LSS or DRR), using the
standard part of the curve (20%) and the entire curve (50%). Each point (d and s) represents the individual
value of the slope (n 4 12).
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of LSS in this group of asthmatics showed that the coefficients of determination (r2) of
LSS20% and LSS50% were all above 0.80. The LSS50% reached statistical significance
in all cases, whereas LSS20% failed to be significant in only one. The low grade of
significance found in this case was probably due to an insufficient number of data
points included in the calculation (three points). Thus, although the relationships be-
tween increasing doses of methacholine and the severity of airway response may have
changed during the test and the methods of calculating the slopes are still open to
debate [1, 2, 10, 12, 23, 26, 28], these results suggested that a linear model can be used
to calculate this index of bronchial hyperresponsiveness in asthmatic patients. In fact,
the linear model is the most frequently used not only in epidemiologic [1, 4, 7, 18, 24]
but also in research protocols [3, 13, 15, 19, 34]. The mean values of DRR20% measured
in our group of patients were well above the cutoff levels between normals and
asthmatics, established with the same method of calculation by Peat et al. [21] and by
Backer [4] in epidemiologic studies in children. However, these values were obtained
from standard bronchial challenge tests with histamine, and it is still not known if the
slopes of DRC to histamine and methacholine in children are comparable [20, 27].
Concerning the least squares method, the LSS20% values found in the present study
were similar or higher than the mean values calculated by Chinn et al. [10] in adult
subjects with symptoms of asthma, and the LSS50% were within the same range as
those measured in clinical trials of adult asthmatic subjects [3, 25].
To our knowledge, no other studies have compared SDRS with MDRS using the
present methods. This may be because most of the maximal bronchial challenge tests
were performed in mild asthmatics who usually exhibited a reproducible plateau re-
sponse, which is generally accepted to describe the shape of DRC. Beyond its useful-
ness in epidemiologic studies, thus avoiding the censoring of data, other groups have
used the slope together with PD and/or plateau to monitor the effects of inhaled
antiinflammatory drugs [3, 25] or natural antigenic exposure in bronchial reactivity of
asthmatics and subjects with allergic rhinitis [7]. In this kind of research, where
moderate and severe asthmatics might be included, the slope may be the only additional
parameter available to describe the shape of DRC. Since the slope is measured on the
steepest part of the DRC, the differences between SDRS and MDRS are expected to be
even higher in more severe asthmatics without plateau than in normal subjects or
patients in whom a stable response is obtained.
Our results suggest that MDRS is the closest measurement of the potential severity
of airway hyperresponsiveness which can be obtained from an artificial situation such
as a bronchial challenge test when a plateau response is absent.
Finally, of the 14 selected asthmatic children, 12 reached a FEV1 decline of 50%
or more from postsaline and exhibited excessive airway narrowing without plateau, and
so the analysis of the shape of DRC could only be provided by PD20 FEV1 and slope.
These results were obtained with cumulative doses of methacholine ranging between
0.117 and 30.08 mmol, well below those administered to mild asthmatics and normal
subjects in maximal bronchial challenge tests. Higher doses of methacholine should be
included in future protocols to study the pathophysiology of maximal airway narrow-
ing.
In conclusion, in this group of asthmatic children the slopes of MDRC could not
be extrapolated from the early part of DRC. Even though it is not clear which segment
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of the slope is more important as a marker of hyperresponsiveness, this should be taken
into account when planning clinical research protocols.
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